Rejected from Journal of Clinical Oncology? The 7 Best Journals to Submit Next

"Practice-changing" threshold. JCO publishes papers that alter clinical guidelines, establish new standards of care, or demonstrate survival benefits from new treatments. A well-designed phase II trial of a new drug combination may be scientifically excellent but won't clear this bar unless the results suggest a realistic path to changing standard treatment.

Phase and study type hierarchy. JCO has an informal hierarchy: definitive phase III randomized trials at the top, followed by large prospective studies, then phase II trials, then retrospective analyses. Single-arm phase II studies, no matter how promising, rarely make it unless the response rate is extraordinary or the unmet need is severe.

Geographic and patient diversity. JCO's editors look for studies that have implications beyond a single institution or country. Single-center retrospective studies, even large ones, are at a disadvantage compared to multi-center or international data.

"Phase II data that would benefit from phase III confirmation." You conducted a promising phase II trial showing activity of a new regimen. The editors agree it's interesting but want to see it confirmed in a randomized phase III setting before publishing it in JCO. This is the most common rejection for drug development papers.

"Retrospective analysis with inherent limitations." You analyzed outcomes from a large single-institution database. The findings are interesting, but selection bias, unmeasured confounders, and the retrospective design limit what the editors are willing to conclude. JCO has become increasingly skeptical of retrospective data for primary endpoints.

"The findings confirm existing evidence." Your trial validates a treatment approach that's already in guidelines. Confirmatory data is valuable, but JCO prioritizes papers that add new information rather than confirm what oncologists already believe.

"Better suited to a subspecialty journal." Your paper focuses on a specific cancer type in a way that's too narrow for JCO's general oncology readership. A paper about treatment sequencing in cholangiocarcinoma might be excellent but too specialized for JCO's broad audience.

"Translational component exceeds clinical relevance." Your paper includes extensive biomarker analysis or molecular characterization alongside clinical data. JCO wants the clinical story to stand on its own. If the main contribution is translational, Clinical Cancer Research or similar journals are better fits.

Before choosing your next journal, a Journal of Clinical Oncology manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

1. Annals of Oncology

Annals of Oncology is published by the European Society for Medical Oncology (ESMO) and is JCO's most direct competitor. With an IF around 50, it publishes practice-changing clinical oncology data, ESMO clinical practice guidelines, and landmark trial results. If JCO rejected your paper but you're confident the clinical evidence is strong enough to change practice, Annals is the natural next submission.

The key difference between JCO and Annals is editorial perspective. Annals has a European editorial board and is particularly receptive to studies with European cohorts, European drug approvals, and ESMO-guideline-relevant data. If your study tested a drug that has EMA but not FDA approval, Annals may see more immediate relevance.

Best for: European clinical trials, ESMO guideline-relevant data, large phase III results, practice-changing oncology evidence.

2. JAMA Oncology

JAMA Oncology has rapidly become one of the top oncology journals, with an IF around 20 and a reputation for publishing comparative effectiveness research, health outcomes data, and clinical studies with policy relevance. If JCO rejected your paper because it focused on health systems outcomes rather than a new drug, JAMA Oncology is likely a better fit.

JAMA Oncology also publishes more epidemiological research than JCO, including cancer screening studies, survivorship research, and disparities research. The journal's editorial perspective values clinical studies that address the entire cancer continuum, from prevention through survivorship.

Best for: Comparative effectiveness, health outcomes, cancer epidemiology, disparities research, screening studies.

3. Clinical Cancer Research

For papers where the translational component is the main contribution, Clinical Cancer Research (AACR journal) is the premier venue. CCR publishes biomarker studies, pharmacokinetic and pharmacodynamic analyses, correlative science from clinical trials, and translational research that bridges lab and clinic.

If JCO rejected your paper because "the main contribution is translational," CCR isn't a consolation prize. It's the right journal. CCR's readership specifically cares about the molecular science behind clinical outcomes, and the journal has a strong track record of publishing work that eventually informs JCO-level clinical trials.

Best for: Biomarker studies, translational oncology, correlative science from trials, molecular profiling, pharmacodynamics.

4. European Journal of Cancer

EJC publishes broad clinical oncology research with a European perspective. The journal is less selective than Annals of Oncology or JCO (acceptance rate around 15%) but maintains strong editorial standards. For well-designed clinical studies that didn't quite clear the "practice-changing" threshold at JCO, EJC is an excellent home.

EJC is also receptive to phase II trials, retrospective analyses with strong methodology, and clinical research in less common cancer types where the patient population limits the feasibility of large randomized trials.

Best for: Phase II trials, European clinical oncology data, rare cancers, clinical research that's strong but not practice-changing.

5. Lancet Oncology

Lancet Oncology is the most ambitious alternative to JCO, with an IF around 50 and similarly rigorous editorial standards. The journal publishes landmark clinical trials, cancer epidemiology, and health policy research with a global perspective. If JCO rejected your paper for reasons unrelated to quality (timing, space, editorial priorities), Lancet Oncology is worth trying.

Be honest about whether your paper is at this level. Lancet Oncology accepts roughly 5% of submissions. But if JCO's rejection was about fit rather than quality, and your trial has genuine global relevance, the different editorial perspective might work in your favor.

Best for: Large international trials, cancer epidemiology with global reach, health policy and cancer, WHO-relevant data.

6. JCO Oncology Practice

JCO Oncology Practice is ASCO's companion journal focused on clinical practice, health services research, quality improvement, and the delivery of cancer care. If JCO rejected your paper because it's about how cancer care is delivered rather than what treatment to give, JCO OP is the right venue.

The journal publishes research on practice patterns, implementation science, clinical workflow optimization, cost-effectiveness, and professional development. Don't overlook it because of the lower IF. If your paper addresses how oncologists practice rather than what they should prescribe, JCO OP's readership is more relevant than a higher-IF journal where the audience doesn't care about practice operations.

Best for: Health services research, practice patterns, cost-effectiveness, quality improvement, cancer care delivery.

7. Cancer

Cancer is the flagship journal of the American Cancer Society and covers all aspects of cancer research, from clinical trials to epidemiology to survivorship. The journal has a broader scope than JCO and accepts a wider range of study types and cancer topics.

For papers that are too specialized for JCO's general audience or that address cancer types where the patient population is small, Cancer provides a well-indexed, high-visibility platform. The journal also publishes strong retrospective studies and registry-based analyses that JCO might decline for design limitations.

Best for: All cancer types, cancer epidemiology, survivorship, registry-based studies, clinical research across tumor types.

Phase III trial rejected? If JCO passed, try Annals of Oncology (European perspective) or Lancet Oncology (global perspective). If those also pass, European Journal of Cancer and Cancer are strong mid-tier options.

Phase II trial rejected? European Journal of Cancer is more receptive to phase II data than JCO. For phase II trials with strong translational components, Clinical Cancer Research values the molecular science alongside the clinical signal.

Translational paper rejected? Go to Clinical Cancer Research. Don't try to force translational work into clinical journals. CCR's editors and readership are specifically looking for the kind of work JCO considers "too translational."

Health services or outcomes research? JAMA Oncology is the top venue for this, followed by JCO Oncology Practice. These journals evaluate health services research on its own merits rather than comparing it unfavorably to randomized trials.

Retrospective analysis? Cancer, European Journal of Cancer, and subspecialty journals (like Breast Cancer Research and Treatment, Gynecologic Oncology, or Lung Cancer) are more receptive to well-designed retrospective studies than JCO.

Clarify the clinical message. JCO rejections often reflect unclear clinical implications. Before resubmitting, make sure the clinical take-home message is stated explicitly in the abstract and the first paragraph of the discussion. What should oncologists do differently based on your findings?

Strengthen the methodology section. If your study is retrospective, address selection bias, confounders, and missing data explicitly. Consider sensitivity analyses to test the stability of your conclusions. Journals below JCO's selectivity still expect rigorous methods.

Separate the translational and clinical stories. If your paper contains both clinical outcomes and translational biomarker data, consider whether splitting them into two papers would strengthen each one. A focused clinical paper for a clinical journal and a focused translational paper for CCR may produce better outcomes than one combined manuscript that doesn't fully satisfy either audience.

Address the sample size question. If JCO's concern was that your study is too small or too preliminary, be transparent about that in your next submission. Framing a small study as hypothesis-generating rather than definitive can align it with journals that accept preliminary evidence.

Clinical oncology is a competitive publishing landscape, and the difference between a JCO paper and an Annals paper often comes down to framing and positioning rather than data quality. Before your next submission, run your manuscript through a manuscript scope and readiness check to check scope alignment, structural completeness, and editorial formatting. Getting the journal match right the first time saves months of review cycles that you could spend on the next trial.

Resubmit to the same tier if:

• Reviewers praised the science but identified fixable issues
• The rejection letter mentioned "consider resubmission after revision"
• You can address every concern within 2-3 months
• No competing paper has appeared since your submission

Move to a different journal if:

• The rejection cited scope mismatch, not quality
• Multiple reviewers questioned novelty or significance
• Your timeline needs a decision within 2-3 months
• A specialist journal's readership would value the work more

Reframe before resubmitting anywhere if:

• Reviewers found fundamental methodology concerns
• The narrative needs restructuring, not just editing
• New experiments or analyses are needed
• The rejection exposed a gap between claims and evidence

In our pre-submission review work with manuscripts targeting the Journal of Clinical Oncology, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Practice-change threshold not met by the study's findings. JCO's editorial standard asks one question above all others: does this change what oncologists do? We see this failure as the most common pattern in JCO desk rejections we review: large, well-powered trials or analyses that confirm the existing standard of care is effective, establish that a known prognostic factor predicts outcomes in a new disease subtype, or demonstrate that an established drug works in a new country's population. In our review of JCO submissions, we find that editors consistently require the finding to require a change in practice or in guideline recommendations, not to validate existing practice.

Surrogate endpoint trials without established validation of the surrogate. JCO values overall survival and patient-reported quality of life outcomes. We see this pattern in JCO submissions we review present progression-free survival, response rate, or disease-free survival as primary endpoints without establishing the surrogate's connection to overall survival in the disease setting studied. Editors consistently require either a validated surrogate or a compelling argument for why overall survival was not feasible as the primary endpoint.

Multi-institutional trials with subgroup findings presented as the primary result. JCO editors scrutinize subgroup analyses carefully. Papers where the primary endpoint did not reach statistical significance but a subgroup analysis did, presented as if the subgroup finding is the central result, face consistent desk rejection for inappropriate statistical framing. We see this failure regularly in manuscripts we review for JCO.

Translational or biomarker substudy without the parent clinical trial context. JCO publishes biomarker and translational substudies from clinical trials, but the parent trial must be clearly contextualized and the subgroup adequately powered. Papers presenting biomarker findings from small substudies without power justification or adequate pre-specification generate consistent editorial concerns.

SciRev community data for JCO confirms desk decisions typically within 1-2 weeks and post-review first decisions within 4-6 weeks, consistent with the fast editorial process ASCO maintains for this flagship clinical oncology journal.